WO2007070680A3 - Optically detectable probes for identification and treatment of tumors - Google Patents

Optically detectable probes for identification and treatment of tumors Download PDF

Info

Publication number
WO2007070680A3
WO2007070680A3 PCT/US2006/047962 US2006047962W WO2007070680A3 WO 2007070680 A3 WO2007070680 A3 WO 2007070680A3 US 2006047962 W US2006047962 W US 2006047962W WO 2007070680 A3 WO2007070680 A3 WO 2007070680A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumors
treatment
optically detectable
identification
detectable probes
Prior art date
Application number
PCT/US2006/047962
Other languages
French (fr)
Other versions
WO2007070680A2 (en
Inventor
Hisataka Kobayashi
Peter Choyke
Original Assignee
Us Gov Health & Human Serv
Hisataka Kobayashi
Peter Choyke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Hisataka Kobayashi, Peter Choyke filed Critical Us Gov Health & Human Serv
Publication of WO2007070680A2 publication Critical patent/WO2007070680A2/en
Publication of WO2007070680A3 publication Critical patent/WO2007070680A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

This disclosure provides compositions and methods for the detection and treatment of intraperitoneal tumors and other tumors. In particular examples, the compositions include an asialoglycoprotein receptor-binding ligand (such as galactosyl serum albumin (GSA) or avidin) conjugated to an optically detectable label, such as a fluorophore. Such compositions can be used to detect and treat tumors, such as tumors that express asialoglycoprotein receptors.
PCT/US2006/047962 2005-12-16 2006-12-15 Optically detectable probes for identification and treatment of tumors WO2007070680A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75142905P 2005-12-16 2005-12-16
US60/751,429 2005-12-16
US84808206P 2006-09-28 2006-09-28
US60/848,082 2006-09-28

Publications (2)

Publication Number Publication Date
WO2007070680A2 WO2007070680A2 (en) 2007-06-21
WO2007070680A3 true WO2007070680A3 (en) 2007-12-27

Family

ID=38163543

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/047962 WO2007070680A2 (en) 2005-12-16 2006-12-15 Optically detectable probes for identification and treatment of tumors

Country Status (1)

Country Link
WO (1) WO2007070680A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008005942A2 (en) * 2006-06-30 2008-01-10 The Govt. Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services. Activatable probes and methods of use
JP2012524904A (en) * 2009-04-21 2012-10-18 ユニバーシティ オブ ユタ リサーチ ファウンデーション Luminescent die for intraoperative imaging or sentinel lymph node biopsy
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
WO2012075028A1 (en) * 2010-11-29 2012-06-07 Dako Denmark A/S Methods and systems for analyzing images of specimens processed by a programmable quantitative assay
US10064943B2 (en) 2014-06-02 2018-09-04 Li-Cor, Inc. Therapeutic and diagnostic probes
AU2015300915B2 (en) 2014-08-08 2020-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Photo-controlled removal of targets in vitro and in vivo
CN110045129B (en) * 2019-04-17 2021-03-26 江南大学 Method for detecting human soluble asialoglycoprotein receptor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859449A (en) * 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
US5958408A (en) * 1995-06-07 1999-09-28 Immunomedics, Inc. Delivery of diagnostic and therapeutic agents to a target site
US6306367B1 (en) * 1996-01-23 2001-10-23 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Fluorescent conjugate for differentiating between diseased and healthy tissues
WO2005082423A2 (en) * 2003-11-18 2005-09-09 Beth Israel Deaconess Medical Center Serum albumin conjugated to fluorescent substances for imaging

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859449A (en) * 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
US5958408A (en) * 1995-06-07 1999-09-28 Immunomedics, Inc. Delivery of diagnostic and therapeutic agents to a target site
US6306367B1 (en) * 1996-01-23 2001-10-23 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Fluorescent conjugate for differentiating between diseased and healthy tissues
WO2005082423A2 (en) * 2003-11-18 2005-09-09 Beth Israel Deaconess Medical Center Serum albumin conjugated to fluorescent substances for imaging

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BAYER E A ET AL: "Avidin- and streptavidin-containing probes", METHODS IN ENZYMOLOGY, vol. 184, 1990, pages 174 - 187, XP008085024, ISSN: 0076-6879 *
BECKER A ET AL: "MACROMOLECULAR CONTRAST AGENTS FOR OPTICAL IMAGING OF TUMORS: COMPARISON OF INDOTRICARBOCYANINE-LABELED HUMAN SERUM ALBUMIN AND TRANSFERRIN", PHOTOCHEMISTRY AND PHOTOBIOLOGY, OXFORD, GB, vol. 72, no. 2, 2000, pages 234 - 241, XP008023884, ISSN: 0031-8655 *
BRASSEUR N ET AL: "Receptor-mediated targeting of phthalocyanines to macrophages via covalent coupling to native or maleylated bovine serum albumin", PHOTOCHEMISTRY AND PHOTOBIOLOGY, OXFORD, GB, vol. 69, no. 3, 1999, pages 345 - 352, XP008085047, ISSN: 0031-8655 *
DESBUQUOIS B ET AL: "Degradation of insulin in isolated liver endosomes is functionally linked to ATP-dependent endosomal acidification.", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 193, 24 October 1990 (1990-10-24), pages 501 - 512, XP002455982 *
HAMA ET AL: "Targeted optical imaging of cancer cells using lectin-binding BODIPY conjugated avidin", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 348, no. 3, 29 September 2006 (2006-09-29), pages 807 - 813, XP005599056, ISSN: 0006-291X *
HAMA Y ET AL: "A Comparison of the Emission Efficiency of Four Common Green Fluorescence Dyes after Internalization into Cancer Cells", BIOCONJUGATE CHEMISTRY, vol. 17, 17 October 2006 (2006-10-17), pages 1426 - 1431, XP002455986 *
HAMA Y ET AL: "In Vivo Spectral Fluorescence Imaging of Submillimeter Peritoneal Cancer Implants Using a Lectin-Targeted Optical Agent", NEOPLASIA, vol. 8, no. 7, July 2006 (2006-07-01), pages 607 - 612, XP002455987 *
HAMBLIN M R ET AL: "PHOTOSENSITIZER TARGETING IN PHOTODYNAMIC THERAPY I. CONJUGATES OF HAEMATOPORPHYRIN WITH ALBUMIN AND TRANSFERRIN", JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B: BIOLOGY, ELSEVIER SCIENCE S.A., BASEL, CH, vol. 26, no. 1, January 1994 (1994-01-01), pages 45 - 56, XP000579859, ISSN: 1011-1344 *
LEE Y C ET AL: "Quantum-dye labeled proteins for glycobiology: a viable nonradioactive alternative tracer", GLYCOBIOLOGY, vol. 8, no. 9, September 1998 (1998-09-01), pages 849 - 856, XP002455983 *
TYCKO B ET AL: "Rapid Acidification of Endocytic Vesicles Containing Asialoglycoprotein in Cells of a Human Hepatoma Line", THE JOURNAL OF CELL BIOLOGY, vol. 97, December 1983 (1983-12-01), pages 1762 - 1776, XP002455984 *
YAO Z ET AL: "Avidin Targeting of Intraperitoneal Tumor Xenografts", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 90, no. 1, 7 January 1998 (1998-01-07), pages 25 - 29, XP002455985 *
YAO Z ET AL: "Imaging of intraperitoneal tumors with technetium-99m GSA", ANNALS OF NUCLEAR MEDICINE, JAPANESE SOCIETY OF NUCLEAR MEDICINE, TOKYO, JP, vol. 12, no. 2, 1998, pages 115 - 118, XP008085056, ISSN: 0914-7187 *

Also Published As

Publication number Publication date
WO2007070680A2 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
WO2007070680A3 (en) Optically detectable probes for identification and treatment of tumors
WO2007120265A3 (en) Coded molecules for detecting target analytes
WO2007136893A3 (en) Anti-fgf19 antibodies and methods using same
WO2008048970A3 (en) Synthetic antibodies
WO2006127537A3 (en) Thyroid fine needle aspiration molecular assay
WO2007028110A3 (en) Methods for using and identifying modulators of delta-like 4
WO2009085209A3 (en) Methods for using and identifying modulators of delta-like 4
WO2006122311A3 (en) Microfluidic chip
WO2008079326A3 (en) Methods for using and identifying modulators of delta-like 4
WO2006038208A3 (en) Agents capable of downregulating an msf-a - dependent hif-1α and use thereof in cancer treatment
WO2007008276A3 (en) Turnover probes and use thereof for nucleic acid detection
WO2009111470A3 (en) Protease assay
WO2008039769A3 (en) Methods and devices for analyzing small rna molecules
WO2006089091A3 (en) Methods for detecting minimum residual disease
WO2006002243A3 (en) Methods of oligosaccharide profiling for the detection of cancer
WO2006090389A3 (en) Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
EA200970062A1 (en) DETERMINATION OF THE AUTHENTICITY OF CONSUMED PRODUCTS USING SUCHARIDES AS MARKERS
WO2005118836A3 (en) Hif prolyl hydroxylase activity assay
WO2007010379A3 (en) Calorimetric assessment of microorganisms and use thereof
WO2007035864A3 (en) Electrophoresis standards, methods and kits
WO2007114986A3 (en) Cooperative probes and methods of using them
PL2211180T3 (en) Use of protein SATB2 as a marker for distinguishing colorectal cancer from other cancers
WO2009140039A3 (en) Synthetic antibodies
WO2008130887A8 (en) Biomarkers for follicular thyroid carcinoma and methods of of use
WO2010075360A3 (en) Methods for detection of sepsis

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06848545

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06848545

Country of ref document: EP

Kind code of ref document: A2